MM-associated circular RNA downregulates microRNA-19a through methylation to suppress proliferation of pancreatic adenocarcinoma cells

Qian, Xinye; Zong, Wenru; Ma, Lei; Yang, Zhoujing; Chen, Wei; Yan, Jun; Xu, Jinzhi

doi:10.1080/21655979.2022.2051815

Cited by 7 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, we explored the expression profile of circRNAs and noted a substantial upregulation of circMYBL2 in both HCC cell lines and tissues. CircMYBL2 has been implicated in various malignancies, including myeloid leukemia, cervical cancer, and pancreatic adenocarcinoma [ 29 – 32 ]. A previous study also identified its involvement in the process of cell proliferation and epithelial-mesenchymal transition, thus contributing to breast cancer progression and liver metastasis [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression

YI,

LI,

YIN

et al. 2024

View full text Add to dashboard Cite

Circular RNAs (circRNAs) have been recognized as pivotal regulators in tumorigenesis, yet the biological functions as well as molecular mechanisms of the majority of circRNAs in hepatocellular carcinoma (HCC) remain elusive. We sought to unveil the expression profile and biological role of circMYBL2 in HCC. Initial microarray analyses were conducted to probe the expression profile of circMYBL2 in HCC cells, and qRT‒PCR analysis was then performed in HCC cell lines and tissues, revealing significant upregulation of circMYBL2. Subsequent experiments were conducted to evaluate the biological function of circMYBL2 in HCC progression. Furthermore, bioinformatics analysis, qRT‒PCR analysis, luciferase reporter assays, and western blot analysis were employed to investigate the interplay among circMYBL2, miR-1205, and E2F1. CircMYBL2 was found to exhibit marked upregulation in tumor tissues as well as HCC cell lines. Elevated expression of circMYBL2 increased the proliferation and migration of HCC cells, whereas circMYBL2 knockdown elicited contrasting effects. Mechanistically, our results indicated that circMYBL2 promoted E2F1 expression and facilitated HCC progression by sponging miR-1205. Our findings revealed that circMYBL2 contributed to HCC progression through the circMYBL2/miR-1205/E2F1 axis, suggesting the potential of circMYBL2 as a novel target for HCC treatment or a prognostic biomarker for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…circMYBL2 is a circRNA originating from the gene MYBL2, which exhibits diverse roles across various cancers the cell cycle checkpoint gene MYBL2, exhibits diverse roles across various cancers [ 29 – 32 ]. The protein encoded by the MYBL2 gene functions as an oncoprotein and is often linked to unfavorable patient outcomes [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression

YI,

LI,

YIN

et al. 2024

View full text Add to dashboard Cite

show abstract

“…Several steatosis scores, such as the SteatoTest™ and the fatty liver index (FLI), have been proposed for steatosis detection, but they do not provide substantial additional information beyond routine clinical, laboratory, and imaging examinations conducted in patients suspected of having NAFLD (8). Non-coding RNAs (ncRNAs), which exhibit aberrant expression associated with NAFLD, have emerged as potential biomarkers for NAFLD pathology, and circulating ncRNAs, including miR-122 and lncRNAs are proposed as potential biomarkers for NAFLD severity and progression (42)(43)(44)(45)(46)(47)(48).…”

Section: Discussionmentioning

confidence: 99%

A gene-based clustering approach reveals QSOX1/IL1RAP as promising biomarkers for the severity of non-alcoholic fatty liver disease

Huang

Cai

et al. 2023

Preprint

View full text Add to dashboard Cite

Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease that ranges from simple steatosis to inflammation, fibrosis, and cirrhosis. To address the unmet need for new NAFLD biomarkers, we aimed to identify candidate biomarkers using publicly available RNA sequencing (RNA-seq) and proteomics data. Methods: A novel approach involving unsupervised gene clustering was performed using homogeneously processed and integrated RNA-seq data of 625 liver specimens to screen for NAFLD biomarkers, in combination with public proteomics data from healthy controls and NAFLD patients. Additionally, we validated the results in the NAFLD and healthy cohorts using enzyme-linked immunosorbent assay (ELISA) of plasma and immunohistochemical staining (IHC) of liver samples. Results: We generated a database (https://dreamapp.biomed.au.dk/NAFLD/) for exploring gene expression changes along NAFLD progression to facilitate the identification of genes and pathways involved in the disease's progression. Through cross-analysis of the gene and protein clusters, we identified 38 genes as potential biomarkers for NAFLD severity. Up-regulation of Quiescin sulfhydryl oxidase 1 (QSOX1) and down-regulation of Interleukin-1 receptor accessory protein (IL1RAP) were associated with increasing NAFLD severity in RNA-seq and proteomics data. Particularly, the QSOX1/IL1RAP ratio in plasma demonstrated effectiveness in diagnosing NAFLD, with an area under the receiver operating characteristic (AUROC) of up to 0.95 as quantified by proteomics profiling, and an AUROC of 0.82 with ELISA. Conclusions: We discovered a significant association between the levels of QSOX1/IL1RAP and NAFLD severity. Furthermore, the QSOX1/IL1RAP ratio shows promise as a non-invasive biomarker for diagnosing NAFLD and assessing its severity. (ChiCTR2300073940).

show abstract

“…По мнению X.Qian и соавт. (2022) нарушение регуляции данного процесса и аномальная экспрессия нк-РНК напрямую связана с возникновением НЖБП [39]. Что примечательно, в недавнем исследовании Z.Fang и соавт.…”

Section: результатыunclassified

Ways to overcome difficulties in diagnosing non-alcoholic fatty liver disease

Alyavi,

Sobirova,

Abdullaev

et al. 2024

jour

View full text Add to dashboard Cite

The purpose of the study is to evaluate the status and capabilities of modern types of diagnostics of non-alcoholic fatty liver disease as part of a meta-analysis of scientific data. Materials and methods. The literature search was carried out in electronic databases Cochrane Library, PubMed.gov, Elsevier.com, Google Scholar. The analysis of the data obtained was focused on works published between 2010 and 2023 (the bias in the form of later studies was used in isolated cases when it came to fundamental scientometric data). Results. After reviewing 693 scientific papers for duplication and inconsistency, 38 sources were selected. Conclusions. The analysis of scientific data revealed that despite the understanding of the pathogenetic causes of non-alcoholic fatty liver disease and the complexity of this disease, liver biopsy still remains the gold standard for assessing liver health. In this regard, there is a need to introduce accessible non-imaging tools and accurate biomarkers, with the help of which it will be possible not only to make an adequate diagnosis, but also to analyze new treatments for NAFLD in clinical trials.

show abstract

MM-associated circular RNA downregulates microRNA-19a through methylation to suppress proliferation of pancreatic adenocarcinoma cells

Cited by 7 publications

References 20 publications

CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression

CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression

A gene-based clustering approach reveals QSOX1/IL1RAP as promising biomarkers for the severity of non-alcoholic fatty liver disease

Ways to overcome difficulties in diagnosing non-alcoholic fatty liver disease

Contact Info

Product

Resources

About